D.A. Davidson & Co’s Emergent Biosolutions EBS Stock Holding History

D.A. Davidson & Co’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,667	Closed	-$217K	–	1142
2018 Q4	$217K	Buy	3,667 +259	+8%	+$16.7K	﹤0.01%	946
2018 Q3	$224K	Buy	+3,408	New	+$199K	﹤0.01%	1029
2018 Q2	–	Sell	-4,048	Closed	-$213K	–	1128
2018 Q1	$213K	Buy	+4,048	New	+$202K	﹤0.01%	979
2017 Q3	–	Sell	-1,200	Closed	-$40K	–	1311
2017 Q2	$40K	Hold	1,200	–	–	﹤0.01%	1603
2017 Q1	$34K	Hold	1,200	–	–	﹤0.01%	1660
2016 Q4	$39K	Hold	1,200	–	–	﹤0.01%	1699
2016 Q3	$37K	Hold	1,200	–	–	﹤0.01%	1641
2016 Q2	$33K	Buy	+1,200	New	+$47K	﹤0.01%	1567

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.A. Davidson & Co's EBS Position: Q1 2019 in Review

D.A. Davidson & Co sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 3,667 shares — an estimated $217K sold.

D.A. Davidson & Co first reported a position in EBS in Q2 2016 and held it in 8 quarters. The position peaked at $224K in Q3 2018. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

D.A. Davidson & Co reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
D.A. Davidson & Co sold 3,667 Emergent Biosolutions shares in Q1 2019, an estimated $217K.
D.A. Davidson & Co first reported a position in Emergent Biosolutions in Q2 2016 and held it in 8 quarters.
D.A. Davidson & Co's Emergent Biosolutions position peaked at $224K in Q3 2018.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on D.A. Davidson & Co's 13F filing for Q1 2019, filed 13 May 2019.